Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
Publication year range
1.
Zhejiang Da Xue Xue Bao Yi Xue Ban ; 37(4): 328-32, 2008 07.
Artículo en Zh | MEDLINE | ID: mdl-18705003

RESUMEN

OBJECTIVE: To develop a mouse model of acute lung injury induced by cigarette smoke (CS) and to investigate inflammatory changes with the model. METHODS: ICR mice exposed to CS for 20-min, 3/d. Bronchoalveolar lavage fluid (BALF) and lung tissue were harvested at d 0, d 1, d 3 and d 7 after CS exposure. Neutrophil count in BAFL, TNF-alpha and MMP-12 levels, the activity of MPO in lung tissue were determined. RESULT: Neutrophil count in BALF, MMP-12 and MPO levels in lung tissue were increased after CS exposure in a time-dependent manner with a peak at d3. TNF-alpha level sharply increased at d1, and remained high level until d7. CONCLUSION: ICR mice are tolerant and sensitive to CS exposure, which may be used as an appropriate animal model for acute lung injury induced by cigarette smoke.


Asunto(s)
Lesión Pulmonar Aguda/inducido químicamente , Modelos Animales de Enfermedad , Nicotiana/efectos adversos , Humo/efectos adversos , Lesión Pulmonar Aguda/patología , Animales , Líquido del Lavado Bronquioalveolar/citología , Masculino , Metaloproteinasa 12 de la Matriz/metabolismo , Ratones , Ratones Endogámicos ICR , Factor de Necrosis Tumoral alfa/metabolismo
2.
Int Immunopharmacol ; 10(4): 406-11, 2010 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-20074667

RESUMEN

In the present study, we investigated the effect of classic PDE4 inhibitor rolipram and novel PDE4 inhibitor ZL-n-91 on LPS-induced acute lung injury (ALI) in mice and its mechanism. ALI was induced in ICR mice by instilling intratracheally with LPS, and mice were divided into seven groups: control (Saline), LPS group, ZL-n-91 (3 microg, 10 microg, and 30 microg kg(-1), ip), Rolipram (1.0 mg kg(-1), ip) and dexamethasone (0.5 mg kg(-1), ip). After the 6h of instilling intratracheally with LPS in mice, total leukocyte number, neutrophil number and protein content in BALF increased rapidly, a large number of neutrophil infiltration around the pulmonary vessel and airway, the lung wet weight/dry weight (w/d)ratio raised significantly. MPO activity, TNF-alpha level and cAMP-PDE, PDE4 activity in lung homogenate raised significantly. P(a)O(2), P(a)CO(2) and PH value in peripheral arterial blood also changed obviously, P(a)O(2) and PH value dropped slightly and P(a)CO(2) increased significantly in LPS group. ZL-n-91 (3 microg, 10 microg, 30 microg kg(-1)) dose-dependently reduced the total leukocyte number, neutrophil number and total protein content in BALF, MPO activity, TNF-alpha level and cAMP-PDE, PDE4 activity in lung homogenate, but the effect of ZL-n-91 in pathological changes and lung wet w/d ratio is slight; Rol and Dex significantly reduced lung wet w/d ratio and improved pathological changes, neutrophil around the pulmonary vessel and airway significantly reduced, symptoms of lung edema relieved; The PH value, P(a)O(2) and P(a)CO(2) in ZL-n-91 high dosage group and Rol group had changes, but there was no significant difference compared with LPS group or saline group; After the administration, the righting reflex recovery time significantly shorten in every group of ZL-n-91. the righting reflex recovery time of Rol group was similar with ZL-n-91 30 microg kg(-1) group, while Dex group was similar with saline group. The present study confirms that the inhibitory effect of ZL-n-91(30 microg kg(-1)) on the inflammatory reactivity, including inhibition of inflammatory cell and protein exudation, MPO and PDE4 activity, improvement of the blood gas, those effects were equivalent with rolipram 1 mg kg(-1), and suggested that ZL-n-91 was stronger than rolipram in PDE4 inhibition. So we speculated that ZL-n-91 may have stronger therapeutic potential for treatment of inflammatory disease than rolipram, meantime have stronger nervous system effect than rolipram.


Asunto(s)
Lesión Pulmonar Aguda/tratamiento farmacológico , Furanos/uso terapéutico , Lipopolisacáridos/antagonistas & inhibidores , Lipopolisacáridos/toxicidad , Éteres Fenílicos/uso terapéutico , Inhibidores de Fosfodiesterasa 4 , Inhibidores de Fosfodiesterasa/uso terapéutico , 3',5'-AMP Cíclico Fosfodiesterasas/metabolismo , Lesión Pulmonar Aguda/inducido químicamente , Anestésicos/antagonistas & inhibidores , Anestésicos/farmacología , Animales , Antiinflamatorios/uso terapéutico , Análisis de los Gases de la Sangre , Líquido del Lavado Bronquioalveolar/química , Líquido del Lavado Bronquioalveolar/citología , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 4/metabolismo , Dexametasona/uso terapéutico , Furanos/antagonistas & inhibidores , Intubación Intratraqueal , Ketamina/antagonistas & inhibidores , Ketamina/farmacología , Lipopolisacáridos/administración & dosificación , Masculino , Ratones , Ratones Endogámicos ICR , Peroxidasa/metabolismo , Éteres Fenílicos/antagonistas & inhibidores , Rolipram/uso terapéutico , Factor de Necrosis Tumoral alfa/metabolismo , Xilazina/antagonistas & inhibidores , Xilazina/farmacología
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda